Table 3.
Hazard Ratios (95% Confidence Intervals)a for Incident Cardiovascular Disease Comparing Types of SGLT2 Inhibitors, MarketScan Databases, 2013–2019
| Dapagliflozin vs. Matched Canagliflozin Users | Dapagliflozin vs. Matched Empagliflozin Users | Empagliflozin vs. Matched Canagliflozin Users | ||||
|---|---|---|---|---|---|---|
| Dapagliflozin (n=11,149) | Canagliflozin (n=11,149) | Dapagliflozin (n=11,680) | Empagliflozin (n=11,680) | Empagliflozin (n=7,689) | Canagliflozin (n=7,689) | |
|
|
||||||
| Composite CVD Outcome | ||||||
| N, events | 247 | 276 | 190 | 225 | 164 | 168 |
| Hazard Ratio (95% CI) | 0.91 (0.77, 1.08) | Reference | 0.85 (0.70, 1.03) | Reference | 0.98 (0.79, 1.22) | Reference |
| Stroke | ||||||
| N, events | 43 | 51 | 33 | 36 | 26 | 31 |
| Hazard Ratio (95% CI) | 0.88 (0.59, 1.33) | Reference | 0.90 (0.56, 1.45) | Reference | 0.87 (0.51, 1.46) | Reference |
| Atrial Fibrillation | ||||||
| N, events | 135 | 144 | 100 | 121 | 89 | 82 |
| Hazard Ratio (95% CI) | 0.96 (0.76, 1.21) | Reference | 0.84 (0.65, 1.10) | Reference | 1.07 (0.80, 1.45) | Reference |
| Myocardial Infarction | ||||||
| N, events | 60 | 80 | 45 | 63 | 48 | 52 |
| Hazard Ratio (95% CI) | 0.75 (0.54, 1.05) | Reference | 0.73 (0.50, 1.07) | Reference | 0.92 (0.62, 1.37) | Reference |
| Heart Failure | ||||||
| N, events | 27 | 32 | 19 | 18 | 13 | 18 |
| Hazard Ratio (95% CI) | 0.90 (0.54, 1.50) | Reference | 1.06 (0.56, 2.02) | Reference | 0.74 (0.36, 1.51) | Reference |
a
Adjusted for age, sex, ICD-9/10 status, propensity score (hypertension, kidney disease, chronic pulmonary disease, depression, metastatic cancer, asthma, ACE inhibitors, alpha-blockers, angiotensin receptor blockers, beta-blockers, calcium channel blockers, loop diuretics, potassium-sparing diuretics, thiazide diuretics, direct vasodilators)
Abbreviations: SGLT2 = sodium-glucose cotransporter-2